Want to see SG:42C full AI Analyst Report?
Total Valuation
iX Biopharma Ltd. has a market cap or net worth of S$453.73M. The enterprise value is S$375.67.
Market CapS$453.73M
Enterprise ValueS$375.67
Share Statistics
iX Biopharma Ltd. has 1,093,315,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,093,315,400
Owned by Insiders24.24%
Owned by Institutions―
Financial Efficiency
iX Biopharma Ltd.’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -44.68%.
Return on Equity (ROE)-0.52
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-44.68%
Return on Capital Employed (ROCE)-0.60
Revenue Per Employee195.80K
Profits Per Employee-228.37K
Employee Count35
Asset Turnover0.26
Inventory Turnover3.70
Valuation Ratios
The current PE Ratio of iX Biopharma Ltd. is ―. iX Biopharma Ltd.’s PEG ratio is 1.55.
PE Ratio―
PS Ratio51.40
PB Ratio22.88
Price to Fair Value22.88
Price to FCF-43.64
Price to Operating Cash Flow-86.03
PEG Ratio1.55
Income Statement
In the last 12 months, iX Biopharma Ltd. had revenue of 6.85M and earned -7.99M in profits. Earnings per share was >-0.01.
Revenue6.85M
Gross Profit2.43M
Operating Income-9.56M
Pretax Income-7.98M
Net Income-7.99M
EBITDA-8.83M
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was -4.72M and capital expenditures -105.00K, giving a free cash flow of -4.82M billion.
Operating Cash Flow-4.72M
Free Cash Flow-4.82M
Free Cash Flow per Share>-0.01
Dividends & Yields
iX Biopharma Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.19
52-Week Price Change2057.89%
50-Day Moving Average0.43
200-Day Moving Average0.28
Relative Strength Index (RSI)37.03
Average Volume (3m)15.11M
Important Dates
iX Biopharma Ltd. upcoming earnings date is Feb 5, 2027, TBA (Confirmed).
Last Earnings DateAug 21, 2026
Next Earnings DateFeb 5, 2027
Ex-Dividend Date―
Financial Position
iX Biopharma Ltd. as a current ratio of 1.86, with Debt / Equity ratio of 162.84%
Current Ratio1.86
Quick Ratio1.74
Debt to Market Cap0.02
Net Debt to EBITDA1.01
Interest Coverage Ratio-13.86
Taxes
In the past 12 months, iX Biopharma Ltd. has paid 9.00K in taxes.
Income Tax9.00K
Effective Tax Rate>-0.01
Enterprise Valuation
iX Biopharma Ltd. EV to EBITDA ratio is -38.87, with an EV/FCF ratio of -42.53.
EV to Sales50.09
EV to EBITDA-38.87
EV to Free Cash Flow-42.53
EV to Operating Cash Flow-43.14
Balance Sheet
iX Biopharma Ltd. has S$5.77M in cash and marketable securities with S$6.73M in debt, giving a net cash position of -S$966.00K billion.
Cash & Marketable SecuritiesS$5.77M
Total DebtS$6.73M
Net Cash-S$966.00K
Net Cash Per Share>-S$0.01
Tangible Book Value Per ShareS$0.02
Margins
Gross margin is 32.20%, with operating margin of -139.52%, and net profit margin of -116.64%.
Gross Margin32.20%
Operating Margin-139.52%
Pretax Margin-116.50%
Net Profit Margin-116.64%
EBITDA Margin-128.89%
EBIT Margin-139.52%
Analyst Forecast
The average price target for iX Biopharma Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast3.27%
EPS Growth Forecast43.59%